Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Brokerages

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has been assigned a consensus rating of “Hold” from the eleven ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.79.

A number of equities research analysts have issued reports on MRNS shares. Jefferies Financial Group reissued a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Monday, September 23rd. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Royal Bank of Canada cut their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th.

Marinus Pharmaceuticals Stock Down 3.5 %

NASDAQ MRNS opened at $0.26 on Friday. The company has a market cap of $14.50 million, a PE ratio of -0.11 and a beta of 1.25. Marinus Pharmaceuticals has a 52 week low of $0.25 and a 52 week high of $11.26. The firm’s 50-day simple moving average is $0.72 and its two-hundred day simple moving average is $1.17.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $28,000. SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth approximately $34,000. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at $64,000. Finally, Values First Advisors Inc. grew its holdings in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 52,257 shares during the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.